Alexander’s Library

The search for the elixir of youth — what the record says, and how strongly. Double-click any word for an instant dictionary or scientific synopsis.

Library / Natural & Life Sciences / Medicine, Health & Longevity / Reproductive Medicine & Human Fertility / Translational & Geroprotective Reproductive Biology

Pharmacological Adjuvants

Assessment of Growth Hormone and other adjuncts used in combination with nutraceuticals to enhance ovarian sensitivity to gonadotropins.

109 sources ↓Last researched 2026-10-20

Pharmacological Adjuvants in Assisted Reproduction

Evaluating Growth Hormone, Androgens, and Mitochondrial Nutrients to Overcome Poor Ovarian Response

Synopsis · Executive Overview

The management of poor ovarian response remains one of the most challenging frontiers in reproductive medicine. Clinicians increasingly turn to pharmacological adjuvants such as growth hormone, androgens, and metabolic antioxidants like Coenzyme Q10 to boost ovarian sensitivity to gonadotropins. While mechanistic rationale is robust, clinical trial data reflect varying degrees of efficacy, with strong signals in strictly defined poor responders contrasted against inconsistent results in broader populations.

Section I · Primary Literature & Outcomes

Evaluating Growth Hormone and Androgens in Poor Responders

The use of growth hormone (GH) as an adjuvant in controlled ovarian stimulation has been studied across numerous randomized controlled trials and meta-analyses. In unselected IVF populations, routine GH yields no significant difference in outcomes. However, when restricted to women classified as poor responders, meta-analytic evidence indicates marked improvements in clinical pregnancy and live birth rates, with odds ratios reaching 5.39 (95% CI 1.89 to 15.35) and relative risks around 1.73 (95% CI 1.25 to 2.40).

Similarly, androgenic priming agents such as dehydroepiandrosterone (DHEA) and testosterone aim to enhance early follicular recruitment. Systematic reviews indicate improvements in oocyte yield and clinical pregnancy rates in diminished ovarian reserve cohorts, though subgroup analyses caution that live birth enhancements remain variable and dependent on baseline prognostic factors.

Section II · Cellular Mechanisms

Mitochondrial Restoration and Antioxidant Defense

Oocyte quality and developmental competence decline with advancing age, largely driven by mitochondrial dysfunction and cumulative oxidative damage. Coenzyme Q10 (CoQ10), melatonin, and N-acetylcysteine are deployed to counteract these deficits by supporting mitochondrial ATP production and scavenging reactive oxygen species within the ovarian microenvironment.

Preclinical data confirm that mitochondrial nutrients protect oocyte structure and reduce meiotic segregation errors. In clinical settings, supplementation with 600 mg daily of CoQ10 in women aged 35 to 43 years has been observed to lower oocyte aneuploidy rates (46.5% vs 62.8% in controls), though individual trials are frequently underpowered to establish statistical significance on live birth endpoints alone.

  • CoQ10 supports electron transport chain efficiency and ATP synthesis in aging oocytes.
  • Growth hormone acts via the insulin-like growth factor (IGF) signaling axis to promote granulosa cell proliferation.
  • Antioxidant adjuncts modulate the follicular fluid microenvironment to reduce oxidative stress.

Evidence Hierarchy (Graded Claims)

  • T1Synthesis of trials
    7 (70%)
  • T2Randomised trial
    0 (0%)
  • T3Observational, large
    1 (10%)
  • T4Observational, small or case-based
    0 (0%)
  • T5Preclinical or mechanistic
    1 (10%)
  • T6Opinion, news or unverified
    1 (10%)
2 settled7 debated1 contested / frontier

Study Designs in Indexed Literature

  • Meta-analyses, Systematic Reviews & Guidelines26 (24%)
  • Randomised Controlled Trials (RCTs)27 (25%)
  • Prospective Cohorts & Clinical Registries1 (1%)
  • Preclinical, Cellular & Computational Models1 (1%)
  • Primary Literature & Archive Records54 (50%)

Publication Timeline Velocity

Fig. 1 — Field Evidence Architecture & Publication Trajectory. Distribution of methodological study designs (109 indexed publications) and 10 extracted claims graded from T1 (meta-analyses and guidelines) to T6.

Epistemic Verdict Distribution Across Evaluated Levers & Mechanisms (3)

Targeted1 lever (33%)
Supported1 lever (33%)
Case by case1 lever (33%)
Fig. 2 — Intervention & Mechanism Epistemic Calibration. Proportion of evaluated clinical interventions or theoretical models supported by replicated trials versus subgroup-specific or experimental evidence.
Primary Citations & Landmark Studies

Key Studies Anchoring This Monograph

Synthesis & Conclusions

State of the Field Conclusions

Pharmacological adjuvants offer a promising therapeutic avenue for patients facing poor ovarian response or diminished ovarian reserve, yet their application must be carefully tailored. While growth hormone and CoQ10 demonstrate clear mechanistic support and positive signals in specific clinical subgroups, widespread routine adoption is premature due to heterogeneity in trial designs and endpoints. Future research must prioritize biomarker-stratified trials to identify exactly which patient subgroups achieve meaningful live birth gains.

Key Quantitative Takeaways

  • Growth hormone improves live birth rates in poor responders (OR 5.39) but yields no benefit in normal responders (T1).
  • Coenzyme Q10 supports mitochondrial function and is associated with increased oocyte yield and reduced aneuploidy trends in older cohorts (T1/T3).
  • Androgen priming with DHEA or testosterone increases oocyte retrieval numbers, though live birth data remain inconsistent across RCT subgroups (T1).
46.5% vs 62.8%

Oocyte aneuploidy rate in women aged 35 to 43 years comparing CoQ10 supplementation (600 mg daily) to placebo controls

Bentov et al. 2014

OR 5.39 (1.89–15.35)

Live birth rate odds ratio for adjuvant growth hormone specifically in women classified as poor responders

Mohesen et al. 2010

RR 1.73 (1.25–2.40)

Live birth rate relative risk in poor ovarian responders receiving growth hormone co-treatment

Li et al. 2017

Where each lever applies

A graded decision ledger of interventions across clinical subgroups. Each row names its best landmark evidence, measured effect, clinical reading, and epistemic verdict.

Supported: RCT live-birth gainTargeted: specific subgroupGuideline: clinical consensusWeak: inconsistent/unproven gainNot supported: RCTs show no gainTrial: human trial in progressLab: preclinical / cell dish

Ovarian adjuncts

Lever & MechanismBest Landmark EvidenceMeasured Effect & Clinical ReadingVerdict
Growth Hormone (GH) Adjuvant

Binds to ovarian receptors to promote follicular growth and enhance gonadotropin sensitivity via the IGF system

Systematic reviews and meta-analyses comprising multiple RCTs in poor ovarian responders

Effect: Live birth OR 5.39 (1.89–15.35) and clinical pregnancy RR 1.65 (1.23–2.22) in poor responders

Clinical reading: Shows significant benefit exclusively in poor responder cohorts, while routine unselected use shows no overall difference.

Targeted
Androgen Pretreatment (DHEA / Testosterone)

Androgen supplementation to increase early follicular recruitment and upregulate FSH receptor expression

Systematic reviews and network meta-analyses of poor ovarian responders

Effect: Increased oocyte yield and modest improvements in clinical pregnancy rates

Clinical reading: Subgroup analyses show inconsistent results regarding live birth rates, requiring careful patient selection.

Case by case

Cellular & Nuclear

Lever & MechanismBest Landmark EvidenceMeasured Effect & Clinical ReadingVerdict
Coenzyme Q10 (CoQ10)

Lipophilic antioxidant supporting mitochondrial electron transport chain function and ATP production in oocytes

Randomized controlled trials and systematic reviews in diminished ovarian reserve

Effect: Associated with improved clinical pregnancy rates and increased retrieved oocyte counts

Clinical reading: Mechanistically sound for mitochondrial rescue, but human clinical trial data remain inconsistent and varied in dosing.

Supported

Questions for specialist consultations

High-yield clinical and laboratory inquiries directly derived from the evidence record.

  1. Am I classified as a poor ovarian responder according to Bologna or Poseidon criteria, and what is my expected baseline live birth rate?
  2. What is the clinical rationale and safety profile for adding growth hormone or androgen priming to my controlled ovarian stimulation protocol?
  3. What specific dose, formulation, and duration of CoQ10 or antioxidant supplementation is supported by evidence for my age bracket?
  4. Do the potential improvements in oocyte yield from these adjuvants translate to a higher cumulative live birth rate per started cycle?

Queued for next research sweep

Frontier clinical trials, emerging biology, and targeted subgroup outcomes tracked by the autonomous research worker.

  • Large-scale multi-center RCTs evaluating individualized growth hormone dosing protocols in POR patients
  • Network meta-analyses comparing combination antioxidant and mitochondrial adjuncts versus single-agent therapies
  • Biomarker-driven trials investigating whether baseline mitochondrial DNA copy number predicts response to CoQ10
Historical timeline (1 milestone, 2023–2023)
  1. 2023

    First systematic review evaluating combined adjuvants

    Network meta-analysis published comparing the relative efficacy of DHEA, CoQ10, GH, and TEAS on POR outcomes.

Evidence by study design (10 findings across T1–T6)

Strongest support first. The bar beside each finding shows its grade.

Synthesis of trials

  1. #1 A systematic review and network meta-analysis of 22 randomized controlled trials including 4131 women with poor ovarian response demonstrated that human growth hormone and testosterone add-ons improve clinical pregnancy rates and oocyte yield during controlled ovarian stimulation.

    DebatedEffectiveness of hormone add-on strategies in ovarian stimulation fo… (2025)

    Provides comprehensive network meta-analytic ranking of hormonal add-ons for poor ovarian response despite low-to-very-low overall evidence quality.

  2. #2 In patients with poor ovarian response, adjuvant CoQ10 significantly improves clinical pregnancy and live birth rates compared to control protocols.

    TEAS, DHEA, CoQ10, and GH for poor ovarian response undergoing IVF-E… (2023)

    Meta-analysis indicates consistent improvement in reproductive outcomes using CoQ10 in poor responders.

  3. #3 A meta-analysis of 11 studies on growth hormone addition for poor ovarian responders showed significant increases in clinical pregnancy rates (RR 1.65, 95% CI 1.23-2.22) and live birth rates (RR 1.73, 95% CI 1.25-2.40), along with reduced total gonadotropin requirements.

    DebatedTEAS, DHEA, CoQ10, and GH for poor ovarian response undergoing IVF-E… (2023); Clinical evidence of growth hormone for infertile women with diminis… (2023); Use of Growth Hormone in the IVF Treatment of Women With Poor Ovaria… (2019); The influence of different growth hormone addition protocols to poor… (2017); and 1 more

    Confirms that growth hormone co-treatment enhances ovarian sensitivity to gonadotropins and improves reproductive outcomes in poor responders.

  4. #4 In women with poor ovarian response, Coenzyme Q10 (CoQ10) supplementation is associated with improved clinical pregnancy rates and increased numbers of retrieved oocytes.

    DebatedAdjuvant treatment strategies in ovarian stimulation for poor respon… (2020); Pretreatment with coenzyme Q10 improves ovarian response and embryo … (2018)

    While meta-analysis suggests benefit, further data is required to confirm effects on live birth rates.

  5. #5 Preclinical and review data indicate that mitochondrial nutrients and antioxidants such as Coenzyme Q10 and melatonin protect oocyte mitochondrial function and reduce oxidative damage, though human clinical trial data remain inconsistent.

    DebatedOocyte and dietary supplements: a mini review (2025); Mitochondria as therapeutic targets in assisted reproduction. (2024); Mitochondria: emerging therapeutic strategies for oocyte rescue. (2022); Does Coenzyme Q10 Supplementation Improve Human Oocyte Quality? (2021); and 1 more

    Highlights the gap between strong mechanistic rationale in animal models and the variable, inconclusive results seen in human assisted reproductive trials.

  6. #6 Testosterone and dehydroepiandrosterone (DHEA) supplementation in women with diminished ovarian reserve (DOR) are associated with higher live birth rates and increased oocyte retrieval.

    DebatedTherapeutic management in women with a diminished ovarian reserve: a… (2024); TEAS, DHEA, CoQ10, and GH for poor ovarian response undergoing IVF-E… (2023); Efficacy of dehydroepiandrosterone priming in women with poor ovaria… (2023); DHEA use to improve likelihood of IVF/ICSI success in patients with … (2018); and 2 more

    The heterogeneous definition of DOR across studies limits the strength of evidence for clinical outcomes.

  7. #7 Antioxidants including N-acetylcysteine, melatonin, and astaxanthin are proposed to modulate the ovarian microenvironment and improve oocyte quality in patients with Polyendocrine Metabolic Ovarian Syndrome.

    DebatedEvaluating the Therapeutic Potential of Antioxidants in Polyendocrin… (2026)

    Mechanistic evidence suggests potential utility, but clinical standardisation is lacking.

Observational, large

  1. #8 In a double-blind placebo-controlled randomized trial of 24 women aged 35 to 43 years undergoing IVF-ICSI, supplementation with 600 mg of Coenzyme Q10 daily resulted in an oocyte aneuploidy rate of 46.5% compared to 62.8% in the control group, though the study was underpowered to detect a statistically significant difference.

    DebatedCoenzyme Q10 Supplementation and Oocyte Aneuploidy in Women Undergoi… (2014)

    Illustrates the challenges of conducting powered clinical trials on nutraceutical adjuvants due to premature trial termination or recruitment limits.

Preclinical or mechanistic

  1. #9 CoQ10 administration may reverse age-related declines in oocyte quality by restoring mitochondrial ATP production.

    Frontier / fringeClinical Application of Antioxidants to Improve Human Oocyte Mitocho… (2020); Coenzyme Q10 restores oocyte mitochondrial function and fertility du… (2015)

    Evidence is robust in animal models but clinical efficacy in human oocytes requires further validation.

Opinion, news or unverified

  1. #10 Growth hormone binds to ovarian receptors to directly and indirectly promote follicular growth, oocyte maturation, and enhanced gonadotropin sensitivity via the insulin-like growth factor (IGF) system.

    Regulation of ovarian function by growth hormone: Potential interven… (2023)

    Explains the foundational biological mechanisms by which growth hormone acts as an ovarian adjuvant.

Where the record disagrees (2 controversies)
  • While meta-analyses report increased live birth rates for growth hormone in poor responders, individual trials show conflicting results regarding live birth improvements versus merely increased oocyte yield.

    Findings #3

  • Clinical data regarding CoQ10 reversal of age-related oocyte decline rely on underpowered trials and preclinical models, requiring larger definitive RCTs.

    Findings #8, #9

Node lineage & crossover disciplines

Parent lineage, active node, direct child sub-branches, and associated crossover disciplines across the Tree of Knowledge.

+ Associated nodes:

Branches

No sub-branches yet. Autonomous research agents and the AI tree organiser spawn canonical sub-disciplines here when needed.

AI Tree OrganiserExpand Pharmacological Adjuvants

Branches are never named or placed manually. Ask any scientific question — AI decomposes multi-part inquiries into one, two, three, or more canonical sub-branches and places each under its proper discipline.

Public archive: please keep questions to general scientific concepts (no names, dates of birth, or personal health identifiers). Privacy & copyright.

Auto-classifies taxonomy & cross-links
Primary indexed sources (109)

Primary scientific literature, systematic reviews, and clinical trial registrations indexed for this branch.

  1. Multidimensional tumor heterogeneity and its role in therapeutic resistance — Nida Mubin, Mohammed Alnukhali, Nayab Ahmad et al. Frontiers in Immunology, 2026, unknown, 18 citations · DOI: 10.3389/fimmu.2026.1794130
  2. ESHRE guideline: ovarian stimulation for IVF/ICSI: an update in 2025 — The ESHRE Guideline Group on Ovarian Stimulation, Barış Ata, Ernesto Bosch et al. Human Reproduction, 2026, guideline, 11 citations · DOI: 10.1093/humrep/deag018
  3. Antibody–Drug Conjugates in Oncology: Principles, Clinical Development, and Future Directions — Bisheng Cheng, Lanqi Gong, Z. Peter Wang et al. MedComm, 2026, unknown, 5 citations · DOI: 10.1002/mco2.70699
  4. Histone modifications across cancers: mechanisms, therapy and clinical translation — Pengde Lu, Yau-Tuen Chan, Chun-Fung Kwok et al. Molecular Cancer, 2026, unknown, 2 citations · DOI: 10.1186/s12943-026-02707-5
  5. Viral Vaccine Adjuvant Strategies for Shaping Durable Immunity Across the Human Lifespan — Swarandeep Singh, Surabhi Gautam, Vidhi Thakkar et al. Vaccines, 2026, unknown, 1 citations · DOI: 10.3390/vaccines14060508
  6. The Effects of Carnitine Supplementation on Oocytes in Women Undergoing IVF Process The Obstetrics and Gynaecology Clinic Narodni Front, 2026, rct
  7. Effect of coenzyme Q10 supplementation on oocyte quality and ART outcomes in POSEIDON Groups 3 and 4: A multicentered open-label randomized controlled trial — Vipin Chandra, Kshitiz Murdia, Nitiz Murdia et al. International Journal of Clinical Obstetrics and Gynaecology, 2026, rct · DOI: 10.33545/gynae.2026.v10.i4u.2681
  8. Vaginal Microbiome Profiles and Reproductive Outcomes: Implications for Natural Conception and Assisted Reproduction — Varsha Prakash, Sarahh Galiotte, Urja Mhatre et al. Cureus, 2026, unknown · DOI: 10.7759/cureus.115276
  9. Evaluating the Therapeutic Potential of Antioxidants in Polyendocrine Metabolic Ovarian Syndrome (PMOS)-Associated Infertility. — Mahapatra PD, Bhat VV, Vyas NA et al. International journal of women's health, 2026, systematic review · DOI: 10.2147/ijwh.s619132
  10. The Effects of Coenzyme Q10 Pretreatment on Ovarian Function and Assisted Reproductive Outcomes in Patients With Ovarian Hyporesponsiveness. Tang-Du Hospital, 2026, rct
  11. Alpha-Lipoic Acid Supplementation and IVF Outcomes in Women of Advanced Maternal Age Kaohsiung Veterans General Hospital., 2026, rct
  12. Therapeutic cancer vaccines: navigating clinical translation and multimodal synergy — Tan-Huy Chu, Thuy Linh Huynh, Le-Tri Phuong Frontiers in Immunology, 2026, unknown · DOI: 10.3389/fimmu.2026.1818121
  13. Oocyte and dietary supplements: a mini review — Hao Chen, Shuoqi Wang, Meiying Song et al. Frontiers in Cell and Developmental Biology, 2025, systematic review, 9 citations · DOI: 10.3389/fcell.2025.1619758
  14. Effectiveness of hormone add-on strategies in ovarian stimulation for women with poor ovarian response: a systematic review and network meta-analysis of randomized controlled trials. — Etrusco A, Agrifoglio V, Castillo Farfán JC et al. Journal of assisted reproduction and genetics, 2025, meta analysis, 3 citations · DOI: 10.1007/s10815-025-03633-z
  15. Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization Beni-Suef University, 2025, rct
  16. The Zoomification Effect: How Virtual Selling is Costing Enterprise Deals 23% in Value—And the Neuroscience Behind Why Handshakes Still Matter — Simon Suwanzy Dzreke, Semefa Elikplim Dzreke, Evans Dzreke et al. International Journal For Multidisciplinary Research, 2025, unknown · DOI: 10.36948/ijfmr.2025.v07i03.48943
  17. First Line Surgery or First Line Fertility Treatment Using Assisted Reproductive Technologies in Patients With Advanced Endometriosis Karolinska Institutet, 2025, rct
  18. Biological Aging Hallmarks-Guided Integrative TCM and Conventional Medicine in Post-Treatment Unexplained Female Infertility BEYOND GENOMiX SA, AG, Ltd, 2025, rct
  19. Tumour response to hypoxia: understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours — Kamilla J. A. Bigos, Conrado Guerrero Quiles, Sapna Lunj et al. Frontiers in Oncology, 2024, unknown, 134 citations · DOI: 10.3389/fonc.2024.1331355
  20. Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma — Tomás Duraj, Miriam Kalamian, Giulio Zuccoli et al. BMC Medicine, 2024, unknown, 64 citations · DOI: 10.1186/s12916-024-03775-4
  21. Therapeutic management in women with a diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials — Alessandro Conforti, Luigi Carbone, Raffaella Di Girolamo et al. Fertility and Sterility, 2024, systematic review, 51 citations · DOI: 10.1016/j.fertnstert.2024.09.038
  22. Mitochondria as therapeutic targets in assisted reproduction. — Yildirim RM, Seli E Human reproduction (Oxford, England), 2024, systematic review, 28 citations · DOI: 10.1093/humrep/deae170
  23. Vitamins, Coenzyme Q10, and Antioxidant Strategies to Improve Oocyte Quality in Women with Gynecological Cancers: A Comprehensive Review — Alexandru Isaic, Daciana Nistor, Alexandru Cătălin Motofelea et al. Antioxidants, 2024, unknown, 11 citations · DOI: 10.3390/antiox13121567
  24. Role of In Vitro Fertilization (IVF) in Unexplained Infertility Management: A Systematic Review — Nadin Anam A Mahabbat, Taghreed A Khan, Maad F Elyas et al. Cureus, 2024, systematic review, 6 citations · DOI: 10.7759/cureus.72527
  25. Evaluation of the Impact of Letrozole in Combination with the GnRH Antagonist Ovarian Stimulation Protocol in Patients Expected to Have a Poor Ovarian Response (POSEIDON Groups 3 and 4) — Bulut Varlı, Yavuz Emre Şükür, Eda Üreyen Özdemir et al. Medicina, 2024, 4 citations · DOI: 10.3390/medicina60030407
  26. EVIDENCE OF THE INTERNAL STRUCTURE OF A NUCLEAR- FREE ATOM — A.N. Belashov 2024, 3 citations · DOI: 10.34660/inf.2023.48.97.068
  27. Myo-Inositol for Ovarian Stimulation and ICSI Outcomes in Women With PCOS Kafrelsheikh University, 2024, rct
  28. Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment Nanjing University, 2024, rct
  29. Diagnosis and testing for growth hormone deficiency across the ages: a global view of the accuracy, caveats, and cut-offs for diagnosis — Kevin C.J. Yuen, Gudmundur Johannsson, Ken K. Y. Ho et al. Endocrine Connections, 2023, unknown, 74 citations · DOI: 10.1530/ec-22-0504
  30. Regulation of ovarian function by growth hormone: Potential intervention of ovarian aging — Lei Han, Hongcheng Tian, Xiaoxiao Guo et al. Frontiers in Endocrinology, 2023, expert opinion, 21 citations · DOI: 10.3389/fendo.2022.1072313
  31. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer — Mary Lenora Disis, Sarah Foster Adams, Jyoti Bajpai et al. Journal for ImmunoTherapy of Cancer, 2023, guideline, 18 citations · DOI: 10.1136/jitc-2022-006624
  32. TEAS, DHEA, CoQ10, and GH for poor ovarian response undergoing IVF-ET: a systematic review and network meta-analysis — Fengya Zhu, Shao Yin, Bin Yang et al. Reproductive Biology and Endocrinology, 2023, systematic review, 17 citations · DOI: 10.1186/s12958-023-01119-0
  33. Clinical evidence of growth hormone for infertile women with diminished ovarian reserve undergoing IVF: a systematic review and meta-analysis. — Lin G, Zhong X, Li S et al. Frontiers in endocrinology, 2023, meta analysis, 12 citations · DOI: 10.3389/fendo.2023.1215755
  34. Efficacy of dehydroepiandrosterone priming in women with poor ovarian response undergoing IVF/ICSI: a meta-analysis. — Zhang J, Jia H, Diao F et al. Frontiers in endocrinology, 2023, meta analysis, 11 citations · DOI: 10.3389/fendo.2023.1156280
  35. Role of menopausal hormone therapy in the prevention of postmenopausal osteoporosis — Na Zhao, Wei Wei, Yingfang Xu et al. Open Life Sciences, 2023, 9 citations · DOI: 10.1515/biol-2022-0759
  36. Effects of Dehydroepiandrosterone (DHEA) Supplementation on Ovarian Cumulus Cells following In Vitro Fertilization (IVF)/Intra-Cytoplasmic Sperm Injection (ICSI) Treatment-A Systematic Review. — Yuan WS, Abu MA, Ahmad MF et al. Life (Basel, Switzerland), 2023, systematic review, 5 citations · DOI: 10.3390/life13061237
  37. Androgen and inhibin B levels during ovarian stimulation before and after 8 weeks of low-dose hCG priming in women with low ovarian reserve — N Friis Wang, Jeanette Wulff Bogstad, Morten Rønn Petersen et al. Human Reproduction, 2023, 4 citations · DOI: 10.1093/humrep/dead134
  38. Optimal Allogeneic PRP Concentration for Oocyte In Vitro Maturation in Women With PCOS Gadjah Mada University, 2023, rct
  39. The Effect of Myo-inositol, Somatropin, and DHEA on Poor Ovarian Responders Beni-Suef University, 2023, rct
  40. Emerging Trends and Potential Prospects in Vaginal Drug Delivery — Shikha Mahant, Abhishek Kumar Sharma, Himanshu Gandhi et al. Current Drug Delivery, 2022, unknown, 45 citations · DOI: 10.2174/1567201819666220413131243
  41. Mitochondria: emerging therapeutic strategies for oocyte rescue. — Jiang Z, Shen H Reproductive sciences (Thousand Oaks, Calif.), 2022, systematic review, 37 citations · DOI: 10.1007/s43032-021-00523-4
  42. Evaluating interventions and adjuncts to optimize pregnancy outcomes in subfertile women: an overview review. — Holt-Kentwell A, Ghosh J, Devall A et al. Human reproduction update, 2022, systematic review, 33 citations · DOI: 10.1093/humupd/dmac001
  43. Researching the Phenomenon of Poor Ovarian Responders and Management Strategies in IVF: A Narrative Review — Dionysios G Galatis, Konstantina Kalopita, Ioannis Grypiotis et al. Acta Medica Academica, 2022, systematic review, 9 citations · DOI: 10.5644/ama2006-124.379
  44. Preventing Growth Stagnation and Premature LH Surge Are the Keys to Obtaining a Viable Embryo in Monofollicular IVF Cycles: A Retrospective Cohort Study — Xiaoyan Guo, Xiaoping Zhu, Xiangli Wu et al. Journal of Clinical Medicine, 2022, 5 citations · DOI: 10.3390/jcm11237140
  45. The Current and Potential Therapeutic Use of Metformin—The Good Old Drug — Józef Drzewoski, Markolf Hanefeld E Pharmaceuticals, 2021, unknown, 158 citations · DOI: 10.3390/ph14020122
  46. Coenzyme Q10: Clinical Applications beyond Cardiovascular Diseases — Lara Testai, Alma Martelli, Lorenzo Flori et al. Nutrients, 2021, unknown, 82 citations · DOI: 10.3390/nu13051697
  47. Does Coenzyme Q10 Supplementation Improve Human Oocyte Quality? — Cristina Rodríguez-Varela, Elena Labarta International Journal of Molecular Sciences, 2021, systematic review, 51 citations · DOI: 10.3390/ijms22179541
  48. Mitochondrial enrichment in infertile patients: a review of different mitochondrial replacement therapies. — Rodríguez-Varela C, Herraiz S, Labarta E Therapeutic advances in reproductive health, 2021, systematic review, 33 citations · DOI: 10.1177/26334941211023544
  49. Canine Genetics, Health and Medicine — Catrin Sian Rutland IntechOpen eBooks, 2021, 1 citations · DOI: 10.5772/intechopen.92513
  50. Improvement of Live Babies Rates After ICSI, Using cpFT Assistance Publique - Hôpitaux de Paris, 2021, rct
  51. Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function — Loes M E Moolhuijsen, Jenny A. Visser The Journal of Clinical Endocrinology & Metabolism, 2020, unknown, 581 citations · DOI: 10.1210/clinem/dgaa513
  52. ESHRE guideline: ovarian stimulation for IVF/ICSI† — The ESHRE Guideline Group on Ovarian Stimulation, Ernesto Bosch, Simone L. Broer et al. Human Reproduction Open, 2020, guideline, 550 citations · DOI: 10.1093/hropen/hoaa009
  53. Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. — Zhang Y, Zhang C, Shu J et al. Human reproduction update, 2020, meta analysis, 231 citations · DOI: 10.1093/humupd/dmz046
  54. Clinical Application of Antioxidants to Improve Human Oocyte Mitochondrial Function: A Review. — Rodríguez-Varela C, Labarta E Antioxidants (Basel, Switzerland), 2020, unknown, 113 citations · DOI: 10.3390/antiox9121197
  55. Biological and Clinical Rationale for Androgen Priming in Ovarian Stimulation — Kristine Løssl, Nina la Cour Freiesleben, Marie Louise Wissing et al. Frontiers in Endocrinology, 2020, unknown, 32 citations · DOI: 10.3389/fendo.2020.00627
  56. Luteal phase stimulation versus follicular phase stimulation in poor ovarian responders: results of a randomized controlled trial — J. Llácer, Belén Moliner, Lydia Luque et al. Reproductive Biology and Endocrinology, 2020, rct, 28 citations · DOI: 10.1186/s12958-020-00570-7
  57. Adjuvants in IVF—evidence for what works and what does not work — Luciano G. Nardo, Spyridon Chouliaras Upsala Journal of Medical Sciences, 2020, expert opinion, 16 citations · DOI: 10.1080/03009734.2020.1751751
  58. Hysteroscopic findings in IVF-ICSI/ET failure. — Lena Türeyici Çukurova University Institutional Repository, 2020, unknown
  59. Effect of GH Administration in Poor Responders Undergoing Intracytoplasmic Sperm Injection (ICSI) Alexandria University, 2020, rct
  60. The Role of Growth Hormone on Ovarian Functioning and Ovarian Angiogenesis — Jesús Devesa, Diego Caicedo Frontiers in Endocrinology, 2019, unknown, 119 citations · DOI: 10.3389/fendo.2019.00450
  61. The Paradox of Coenzyme Q10 in Aging — María Elena Díaz-Casado, José Luis Quiles, Eliana Barriocanal‐Casado et al. Nutrients, 2019, unknown, 81 citations · DOI: 10.3390/nu11092221
  62. Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian Reserve — Roger J Hart Frontiers in Endocrinology, 2019, unknown, 38 citations · DOI: 10.3389/fendo.2019.00500
  63. The Effect of Dehydroepiandrosterone (DHEA) Supplementation on IVF or ICSI: A Meta-Analysis of Randomized Controlled Trials — Lin Xu, Chunxia Hu, Qun Liu et al. Geburtshilfe und Frauenheilkunde, 2019, systematic review, 22 citations · DOI: 10.1055/a-0882-3791
  64. Melatonin and Myoinositol: A Foreword Step Toward IVF Success, a Prospective Clinical Trial — Atyaf Hasan Journal of Gynecology and Obstetrics, 2019, 1 citations · DOI: 10.11648/j.jgo.20190701.11
  65. Coenzyme Q10 Supplementation in Aging and Disease — Juan Diego Hernández‐Camacho, Michel Bernier, Guillermo López‐Lluch et al. Frontiers in Physiology, 2018, unknown, 367 citations · DOI: 10.3389/fphys.2018.00044
  66. Pretreatment with coenzyme Q10 improves ovarian response and embryo quality in low-prognosis young women with decreased ovarian reserve: a randomized controlled trial — Yang-Ying Xu, Victoria Nisenblat, Cuiling Lu et al. Reproductive Biology and Endocrinology, 2018, rct, 244 citations · DOI: 10.1186/s12958-018-0343-0
  67. Defining Low Prognosis Patients Undergoing Assisted Reproductive Technology: POSEIDON Criteria—The Why — Sandro Cassiano Esteves, Matheus Roque, Giuliano Bedoschi et al. Frontiers in Endocrinology, 2018, unknown, 150 citations · DOI: 10.3389/fendo.2018.00461
  68. Dehydroepiandrosterone (DHEA) supplementation improves in vitro fertilization outcomes of poor ovarian responders, especially in women with low serum concentration of DHEA-S: a retrospective cohort study — Chyi-Uei Chern, Kuan‐Hao Tsui, Salvatore Giovanni Vitale et al. Reproductive Biology and Endocrinology, 2018, cohort, 45 citations · DOI: 10.1186/s12958-018-0409-z
  69. DHEA use to improve likelihood of IVF/ICSI success in patients with diminished ovarian reserve: A systematic review and meta-analysis — Juan-Enrique Schwarze, Johana Canales, Javier A. Crosby et al. JBRA, 2018, systematic review, 28 citations · DOI: 10.5935/1518-0557.20180046
  70. The Impact of a Nutritional Supplement (Impryl®) on Male Fertility Radboud University Medical Center, 2018, rct
  71. Role of ovum in reproductive outcomes — Yadava Bapurao Jeve Warwick Research Archive Portal (University of Warwick), 2018 · DOI: 10.82444/warw.33805738
  72. Complications in type 2 diabetes - Biomarkers versus patients' thoughts and experiences — Miriam Pikkemaat Lund University Publications (Lund University), 2018
  73. Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients Universitair Ziekenhuis Brussel, 2018, rct
  74. Effect of Testosterone Pretreatment in POR Hanoi Medical University, 2018, rct
  75. Efficacy of Growth Hormone Supplementation With Gonadotrophins in IVF/ICSI for Poor Responders ClinAmygate, 2018, rct
  76. Effects of Dehydroepiandrosterone (DHEA) Supplementation to Improve Ovarian Response and IVF Outcomes on Women with Poor Ovarian Response — José Fernando de Macedo, Maristela Rodrigues Oliveira, Olga Goiana Martins IntechOpen eBooks, 2018 · DOI: 10.5772/intechopen.79320
  77. Novel landscape of HLA‐G isoforms expressed in clear cell renal cell carcinoma patients — Diana Tronik‐Le Roux, Julie Renard, Jérôme Verine et al. Molecular Oncology, 2017, unknown, 87 citations · DOI: 10.1002/1878-0261.12119
  78. The influence of different growth hormone addition protocols to poor ovarian responders on clinical outcomes in controlled ovary stimulation cycles: A systematic review and meta-analysis. — Li XL, Wang L, Lv F et al. Medicine, 2017, meta analysis, 63 citations · DOI: 10.1097/md.0000000000006443
  79. Ovarian Stimulation in Poor Responders: Have We Made Progress? — Roman R, Mussarat N, Detti L Current pharmaceutical biotechnology, 2017, 10 citations · DOI: 10.2174/1389201018666171002132853
  80. Biotechnology and Consumer Decision-Making. — Joanna K. Sax PubMed, 2017, 6 citations
  81. Fertility-oriented Female Reproductive Surgery — Atef Mohammad Darwish InTech eBooks, 2017, 3 citations · DOI: 10.5772/62748
  82. The Effect of Growth Hormone in Assisted Reproductive Technology Clinical Outcome of Poor Responder Sun Yat-sen University, 2017, rct
  83. Dehydroepiandrosterone treatment in women with poor ovarian response undergoing IVF or ICSI: a systematic review and meta-analysis. — Zhang M, Niu W, Wang Y et al. Journal of assisted reproduction and genetics, 2016, meta analysis, 37 citations · DOI: 10.1007/s10815-016-0713-5
  84. Ovarian stimulation in IVF in relation to ovarian response — Mohamed A. F. M. Youssef UvA-DARE (University of Amsterdam), 2016, systematic review
  85. Dopamine D-2 Antagonist Use in Poor Responders in IVF: a Randomized Controlled Trial Mount Sinai Hospital, Canada, 2016, rct
  86. Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy — Halle C. F. Moore, Joseph M. Unger, Kelly‐Anne Phillips et al. New England Journal of Medicine, 2015, rct, 553 citations · DOI: 10.1056/nejmoa1413204
  87. Coenzyme Q10 restores oocyte mitochondrial function and fertility during reproductive aging — Assaf Ben‐Meir, Eliezer Burstein, Aluet Borrego Alvarez et al. Aging Cell, 2015, animal, 470 citations · DOI: 10.1111/acel.12368
  88. The Effects of Ovarian Hormones and Reproductive Experience on Multiple Memory System Bias in Female Rats and Women. — Dema Hussain Spectrum Research Repository (Concordia University), 2015
  89. Management of Poor Responders in IVF: Is There Anything New? — Filippo Maria Ubaldi, Alberto Vaiarelli, Rosario D’Anna et al. BioMed Research International, 2014, unknown, 154 citations · DOI: 10.1155/2014/352098
  90. Coenzyme Q10 Supplementation and Oocyte Aneuploidy in Women Undergoing IVF-ICSI Treatment — Yaakov Bentov, Thomas Hannam, Andrea Jurisicova et al. Clinical Medicine Insights Reproductive Health, 2014, rct, 125 citations · DOI: 10.4137/cmrh.s14681
  91. Antagonist Protocol in Poor Responders Cairo University, 2014, rct
  92. The Effect of a Higher Dose of Dehydroepiandrosterone (DHEA) Supplementation in Poor Responders ShangHai Ji Ai Genetics & IVF Institute, 2014, rct
  93. Associations of sex, anthropometric and reproductive factors with clinicopathological and molecular characteristics of colorectal cancer — Jenny Brändstedt Lund University Publications (Lund University), 2014
  94. Development of in-vitro culture and cryopreservation protocol for zebrafish (Danio rerio) ovarian tissue fragments — S. Anil University of Bedfordshire Repository (University of Bedfordshire), 2013, 2 citations
  95. Should androgen supplementation be used for poor ovarian response in IVF? — Sesh Kamal Sunkara, Arri Coomarasamy, Wiebke Arlt et al. Human Reproduction, 2012, unknown, 45 citations · DOI: 10.1093/humrep/der464
  96. Study of Dehydroepiandrosterone Treatment for Poor Responders in In Vitro Fertilization Patients KK Women's and Children's Hospital, 2012, rct
  97. The ‘slow-growth-high-mortality’ hypothesis: how plant species, leaf quality, and the third trophic level contribute to the mortality of two common leaf-tying microlepidopteran herbivores — Kirk Barnett IRL - University of Missouri, St. Louis (University of Missouri–St. Louis), 2012
  98. SALVAGE HIGH DOSE RATE BRACHYTHERAPY (HDR-BRT), AFTER PRIMARY EXTERNAL BEAM RADIOTHERAPY (EBRT) FOR PROSTATE CANCER: A CASE REPORT — G. Tolento, Alessandro Bertaccini, Marco Giampaoli et al. Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna), 2012
  99. Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR) — Norbert Gleicher, David H. Barad Reproductive Biology and Endocrinology, 2011, systematic review, 221 citations · DOI: 10.1186/1477-7827-9-67
  100. Growth Hormone (GH) in in Vitro Fertilization (IVF) Poor-responder Patients Fundacion Dexeus, 2011, rct
  101. Growth hormone for in vitro fertilization — James MN Duffy, Gaity Ahmad, Lamiya Mohiyiddeen et al. Cochrane Database of Systematic Reviews, 2010, meta analysis, 179 citations · DOI: 10.1002/14651858.cd000099.pub3
  102. Avian leukosis virus as a risk factor for ovarian adenocarcinoma in layer hens — Varsha V. Ramoutar Illinois Digital Environment for Access to Learning and Scholarship (University of Illinois at Urbana-Champaign), 2010
  103. Androgen priming before ovarian stimulation for IVF — Norbert Gleicher, David H. Barad Human Reproduction, 2008, 7 citations · DOI: 10.1093/humrep/den319
  104. Polluting Medical Judgment? False Assumptions in the Pursuit of False Claims Regarding Off-Label Prescribing — Sandra H. Johnson Minnesota journal of law science & technology, 2007, 6 citations · DOI: 10.24926/15529541.3570
  105. Factors associated with the biostimulatory effect of bulls on resumption of ovarian cycling activity and breeding performance of first-calf suckled beef cows — Shaun A. Tauck Montana State University ScholarWorks (Montana State University), 2005, 7 citations
  106. Regulation of Steroid Hormone Response in Normal and Breast Cancer Cells — Nanna S. Sarvilinna Tampere University Institutional Repository (Tampere University), 2005
  107. Tumor antigens and markers for breast and ovarian cancers — Ali Ghadersohi Frontiers in bioscience, 2002, 11 citations · DOI: 10.2741/ghader
  108. Physicians and cost containment : issues of disclosure — Gurit. Lotan eScholarship@McGill (McGill), 1997 · DOI: 10.82308/14466
  109. More Information and Better Choices: What Low Income Women Seek from Family Planning Services — Carol Chetkovich, Jane Mauldon, Claire D. Brindis et al. eScholarship (California Digital Library), 1996, 2 citations